This analysis demonstrates the association of autoantibodies with treatment response in KRAS-mutant NSCLC, suggesting potential biomarkers for therapy effectiveness.
Developing effective therapies for KRAS-mutant non–small cell lung cancer (NSCLC) remains challenging. Although the combined use of the MEK inhibitor trametinib and the RTK inhibitor anlotinib has shown promising preclinical and clinical activity, reliable biomarkers to predict treatment response are still lacking.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: